| Period 1 | Period 2 | Period 3 | Period 4 | Period 5 | All Periods | ||
| A. Availability of tests for presumptive patients | |||||||
| Test performed | n = 595 (%) | n = 1023 (%) | n = 1446 (%) | n = 2148 (%) | n = 1300 (%) | N = 6512 (%) | |
| Culture solid L-J | 594 (99.8) | 1021 (99.8) | 1141 (78.9) | 1226 (57.1) | 694 (53.4) | 4676 (71.8) | |
| Drug sensitivity test | 434 (72.9) | 588 (57.5) | 397 (27.5) | 432 (20.1) | 180 (13.8) | 2031 (31.2) | |
| GeneXpert MTB/RIF | - | - | 36 (2.5) | 668 (31.1) | 608 (46.8) | 1312 (26.8) | |
| Culture LJ and/or Xpert MTB/RIF | 594 (99.8) | 1021 (99.8) | 1166 (80.6) | 1701 (79.2) | 925 (71.2) | 5407 (83.0) | |
| B. Patterns of resistance to first line anti-TB drugs | |||||||
| Profile of resistance | n = 434 (%) | n = 588 (%) | n = 397 (%) | n = 432 (%) | n = 180 (%) | N = 2031 (%) | [IC95%] |
| Sensible to all drugs | 129 (29.7) | 223 (37.9) | 256 (64.5) | 147 (34.0) | 71 (39.4) | 826 (40.7) | [38.6 - 42.8] |
| Resistance to H | 278 (64.1) | 306 (52) | 124 (31.2) | 215 (49.8) | 95 (52.8) | 1018 (50.1) | [47.9 - 52.3] |
| Resistance to R | 243 (56.0) | 289 (49.1) | 90 (22.7) | 208 (48.1) | 96 (53.3) | 926 (45.6) | [43.4 - 47.8] |
| Resistance to E | 241 (55.5) | 306 (52) | 120 (30.2) | 242 (56.0) | 105 (58.3) | 1014 (49.9) | [47.8 - 52.1] |
| Resistance to S | 216 (49.8) | 219 (37.2) | 97 (24.4) | 123 (28.5) | 72 (40.0) | 727 (35.8) | [33.7 - 37.9] |
| Total mono resistance | 26 (5.9) | 46 (7.8) | 16 (4.0) | 64 (14.8) | 3 (1.7) | 155 (7.6) | [5.8 - 10.2] |
| Mono resistance to H | 12 (2.8) | 7 (1.2) | 6 (1.5) | 5 (1.2) | 0 (0) | 30 (1.5) | [1.0 - 2.1] |
| Mono resistance to R | 3 (0.7) | 4 (0.7) | 0 (0) | 6 (1.4) | 1 (0.6) | 14 (0.7) | [0.4 - 1.2] |
| Mono resistance to E | 5 (1.2) | 26 (4.4) | 8 (2.0) | 52 (12) | 2 (1.1) | 93 (4.6) | [3.8 - 5.6] |
| Mono resistance to S | 6 (1.4) | 9 (1.5) | 2 (0.5) | 1 (0.2) | 0 (0) | 18 (0.9) | [0.6 - 1.4] |
| Total multidrug resistance | 229 (52.8) | 271 (48.6) | 85 (21.4) | 193 (44.7) | 91 (50.6) | 869 (42.8) | [38.4 - 47.8] |
| H-R | 12 (2.8) | 13 (2.2) | 6 (1.5) | 15 (3.5) | 2 (1.1) | 48 (2.4) | [1.8 - 3.1] |
| H-R-E | 42 (9.7) | 77 (13.1) | 9 (2.3) | 65 (15) | 26 (14.4) | 219 (10.8) | [9.5 - 12.2] |
| H-R-S | 22 (5.1) | 21 (3.6) | 6 (1.5) | 15 (3.5) | 0 (0) | 64 (3.2) | [2.5 - 4.0] |
| H-R-E-S | 153 (35.3) | 160 (27.2) | 64 (16.1) | 98 (22.7) | 63 (35) | 538 (26.5) | [24.6 - 28.5] |
| Total poly resistance | 50 (11.5) | 48 (8.2) | 40 (10.1) | 28 (6.5) | 15 (8.3) | 181 (8.9) | [6.4 - 12.8] |
| H-E | 10 (2.3) | 12 (2.0) | 14 (3.5) | 13 (3.0) | 2 (1.1) | 51 (2.5) | [1.9 - 3.3] |
| H-S | 10 (2.3) | 5 (0.9) | 3 (0.8) | 1 (0.2) | 1 (0.6) | 20 (1.0) | [0.6 - 1.5] |
| H-E-S | 17 (3.9) | 11 (1.9) | 16 (4.0) | 3 (0.7) | 1 (0.6) | 48 (2.4) | [1.8 - 3.1] |
| E-S | 2 (0.5) | 6 (1) | 2 (0.5) | 2 (0.5) | 3 (1.7) | 15 (0.7) | [0.5 - 1.2] |
| R-E | 5 (1.2) | 7 (1.2) | 1 (0.3) | 6 (1.4) | 4 (2.2) | 23 (1.1) | [0.8 - 1.7] |
| R-S | 0 (0) | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) | [0.0 - 0.3] |
| R-E-S | 6 (1.4) | 6 (1) | 4 (1.0) | 3 (0.7) | 4 (2.2) | 23 (1.1) | [0.8 - 1.7] |
| C. The proportion of RR-/MDR-TB versus non RR-/MDR-TB | |||||||
|
| n = 434 (%) | n = 588 (%) | n = 426 (%) | n = 964 (%) | n = 739 (%) | N = 3151 (%) | [IC 95%] |
| RR-/MDR-TB | 243 (56.0) | 289 (49.2) | 97 (22.8) | 434 (45.0) | 501 (67.8) | 1564 (49.6) | [47.9 - 51.4] |
| Non RR-/MDR-TB | 191 (44.0) | 299 (50.8) | 329 (77.2) | 530 (55.0) | 238 (32.2) | 1587 (50.4) | [48.6 -52.1] |